ホーム › アトピー性皮膚炎（湿疹） › アーカンソー州
アーカンソー州におけるアトピー性皮膚炎（湿疹）の臨床試験
アーカンソー州内の拠点で、アトピー性皮膚炎（湿疹）に関する8件の研究が参加者を募集しています。
アーカンソー州内の都市
公式研究テキスト（英語）
Platform Study to Evaluate the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis
- Novartis Investigative Site, Fort Smith
被験者募集中第2相
18歳〜100歳 · 全性別 · 2026/09/28更新 · NCT06947993Study of ENV-294 in Adults With Moderate-to-Severe Atopic Dermatitis
- Enveda Investigative Site, Hot Springs
被験者募集中第2相
18歳〜75歳 · 全性別 · 2026/09/25更新 · NCT07298395A Long-term Study of the Medicine Called Abrocitinib in Children Aged 2 Years and Older With Moderate to Severe Eczema
- Arkansas Research Trials, North Little Rock
被験者募集中第3相
2歳〜11歳 · 全性別 · 2026/09/25更新 · NCT06807281A Phase 2b Study of the Effects of Camoteskimab in Adults With Moderate-to-Severe Atopic Dermatitis
- Dermatology Trial Associates, Inc, Bryant
被験者募集中第2相
18歳〜65歳 · 全性別 · 2026/08/28更新 · NCT07599813A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis
- Applied Research Center and Wellness Clinic /ID# 268547, Little Rock
被験者募集中第3相
2歳〜11歳 · 全性別 · 2026/08/06更新 · NCT06461897A Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Children and Infants With Moderate-to-severe Atopic Dermatitis
- Leo Pharma Investigational site, North Little Rock
被験者募集中第3相
6 Months – 11 Years · 全性別 · 2026/07/07更新 · NCT06311682A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab
- Clinical Trials Institute - Northwest Arkansas /ID# 267290, Fayetteville
被験者募集中第3相
18歳〜63歳 · 全性別 · 2026/07/06更新 · NCT06389136A Study to Investigate the Safety, Tolerability, and Efficacy of BxC-I17e Single and Multiple Dose SC Injection in Patients With Moderate to Severe Atopic Dermatitis
- Arkansas Research Trials, North Little Rock
被験者募集中第1相
18歳以上 · 全性別 · 2025/09/19更新 · NCT06055361ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。